Ofloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients.
BACKGROUND
The efficacy and safety of oral ofloxacin were compared with those of vancomycin/polymyxin for prophylaxis of bacterial infections in granulocytopenic patients undergoing chemotherapy for hematologic malignancy.


METHODS
Antimicrobial prophylaxis was begun at the time of initiation of chemotherapy. Thirty patients received ofloxacin tablets (300 mg orally every 12 hours) plus a nystatin suspension. Thirty-two patients received vancomycin capsules (500 mg orally every eight hours) and polymyxin capsules (100 mg orally every eight hours) plus a nystatin suspension.


RESULTS
In the group of patients receiving ofloxacin, there were a lower number of acquired gram-negative bacillary organisms per patient (0.13 versus 1.37, p less than 0.00005), fewer patients with documented infection (11 of 30 versus 21 of 32, p = 0.04), and fewer cases of gram-negative septicemia (zero of 30 versus five of 32, p = 0.05). Ofloxacin was also better tolerated (24 of 30 versus 10 of 32 patients highly compliant, p = 0.01) and associated with fewer gastrointestinal side effects (one of 30 versus nine of 32 patients with gastrointestinal side effects, p = 0.01) than vancomycin/polymyxin. However, except for a reduction of Staphylococcus aureus colonization and infection by ofloxacin, neither ofloxacin nor vancomycin/polymyxin was effective in eliminating colonization or infection with viridans group streptococci, coagulase-negative staphylococci, or other gram-positive organisms. Only three isolates of ofloxacin-resistant gram-negative bacteria (Pseudomonas fluorescens, Pseudomonas putida, and Enterobacter aerogenes) were isolated from surveillance cultures, but none caused infection.


CONCLUSIONS
These results suggest that oral ofloxacin is a more tolerable and efficacious alternative to vancomycin/polymyxin for prevention of serious gram-negative bacillary infections in granulocytopenic patients. More effective prophylaxis of gram-positive infections, however, is still needed.
Winston
D J
DJ
Department of Medicine, UCLA Center for the Health Sciences.
Ho
W G
WG
Bruckner
D A
DA
Gale
R P
RP
Champlin
R E
RE
D000293:Adolescent; D000328:Adult; D000368:Aged; D000380:Agranulocytosis / Q000209:etiology / Q000382:microbiology*; D001419:Bacteria / Q000302:isolation & purification; D001424:Bacterial Infections / Q000382:microbiology / Q000517:prevention & control*; D004064:Digestive System / Q000382:microbiology; D004359:Drug Therapy, Combination; D005260:Female; D005658:Fungi / Q000302:isolation & purification; D006801:Humans; D007938:Leukemia / Q000150:complications; D008297:Male; D008875:Middle Aged; D009305:Nasopharynx / Q000382:microbiology; D015242:Ofloxacin / Q000008:administration & dosage / Q000627:therapeutic use*; D011113:Polymyxins / Q000008:administration & dosage* / Q000627:therapeutic use; D014640:Vancomycin / Q000008:administration & dosage* / Q000627:therapeutic use
D011113:Polymyxins; D014640:Vancomycin; D015242:Ofloxacin